| 000 | 04036naa a22005177i 4500 | ||
|---|---|---|---|
| 001 | UMUN-OA-20261005-MLS-027 | ||
| 003 | local | ||
| 005 | 20261005174903.0 | ||
| 006 | m o d | ||
| 007 | cr|||||||||||| | ||
| 008 | 261005s2023 xx o u000 0 eng d | ||
| 024 | 7 |
_a10.3390/genes14071314 _2doi |
|
| 035 | _a(local)EuropePMC:PMC10379610 | ||
| 040 |
_alocal _beng _clocal |
||
| 041 | 0 | _aeng | |
| 100 | 0 |
_aBayan Alzumaili _eauthor. |
|
| 245 | 1 | 0 |
_aUpdate on Molecular Diagnostics in Thyroid Pathology: A Review. / _cBayan Alzumaili; Peter M Sadow. |
| 264 | 1 |
_a[Place of publication not identified] : _bMultidisciplinary Digital Publishing Institute (MDPI), _c2023. |
|
| 300 | _a1 online resource (1 article). | ||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 500 | _aPublication type: Review article. | ||
| 500 | _aLinked open-access copy: published version. | ||
| 506 | 0 |
_aOpen access; no subscription required for the linked open-access version. _fUnrestricted online access _2star |
|
| 520 | 3 | _aThyroid nodules are quite common, and the determination of a nodule of concern is complex, involving serum testing, radiology and, in some cases, pathological evaluation. For those nodules that raise clinical concern of neoplasia, fine needle aspiration biopsy is the gold standard for evaluation; however, in up to 30% of cases, results are indeterminate for malignancy, and further testing is needed. Advances in molecular testing have shown it to be of benefit for both diagnostic and prognostic purposes, and its use has become an integral part of thyroid cancer management in the United States and in several global nations. After The Cancer Genome Atlas (TCGA) consortium published its molecular landscape of papillary thyroid carcinoma (PTC) and reduced the "black matter" in PTC from 25% to 3.5%, further work ensued to clarify the remaining fraction not neatly attributed to the BRAF V600E -like or RAS -like phenotypes of the TCGA. Over the past decade, commercial molecular platforms have been refined as data accrues, and they increasingly cover most genetic variants of thyroid carcinomas. Molecular reporting focuses on the nodule tested, including related clinical information for that nodule (size of nodule, Bethesda category, etc.). This results in a comprehensive report to physicians that may also include patient-directed, clear language that facilitates conversations about nodule management. In cases of advanced or recurrent disease, molecular testing may become essential for devising an individual therapeutic plan. In this review, we focus on the evolution of integrated molecular testing in thyroid nodules, and how our understanding of tumor genetics, combined with histopathology, is driving the next generation of rational patient management, particularly in the context of emerging small, targetable therapeutics. | |
| 540 |
_aCreative Commons Attribution. See the linked licence for the applicable terms. _uhttps://creativecommons.org/licenses/by/4.0/ |
||
| 546 | _aIn English. | ||
| 588 | 0 | _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source. | |
| 590 | _aCourse allocation: B. Sc. Medical Laboratory Science. | ||
| 650 | 4 | _aThyroid carcinoma | |
| 650 | 4 | _aRas | |
| 650 | 4 | _athyroid | |
| 650 | 4 | _aThyroid cancer | |
| 650 | 4 | _aMolecular Diagnostics | |
| 650 | 4 | _aBraf | |
| 653 | _aB. Sc. Medical Laboratory Science | ||
| 653 | _aUMUN open access collection | ||
| 653 | _amolecular diagnostics | ||
| 655 | 4 | _aReview articles. | |
| 700 | 0 |
_aPeter M Sadow _eauthor. |
|
| 773 | 0 |
_tGenes _gVol. 14, no. 7, (2023), pages/article 1314 _x2073-4425 |
|
| 856 | 4 | 0 |
_uhttps://europepmc.org/articles/PMC10379610 _yRead open-access publication _zOpen access. _70 |
| 884 |
_aCourse selection and automated MARC21 enrichment from Europe PMC metadata. _g20261005 _khttps://europepmc.org/articles/PMC10379610 _qlocal |
||
| 942 | _n0 | ||
| 999 |
_c1169 _d1169 |
||